Kintor Pharma Shares Rise as Skin Tone Treatment Inches Closer to Approval After Trial Results
MT Newswires Live
Sep 07
Kintor Pharmaceutical (HKG:9939) has disclosed positive results from the long-term safety trial of its skin tone correcting treatment, KT-939, according to a Monday bourse filing.
Preliminary data showed that KT-939 was safe and well-tolerated, and participants treated with it for about a year did not experience any adverse skin reactions, the company said.
Kintor said it is now working to advance KT-939's registration application for approval by the National Medical Products Administration before launching it commercially.
The company's shares are up 5.5% in midday trading on the HKEX.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.